Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Gruenloh

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|April 26, 2011
Combining ion pairing agents for enhanced analysis of oligonucleotide therapeutics by reversed phase-ion pairing ultra performance liquid chromatography (UPLC)Daren S Levin, Benjamin T Shepperd, Christopher J Gruenloh
Oligonucleotides|October 28, 2010
Chemistry at the 2' position of constituent nucleotides controls degradation pathways of highly modified oligonucleotide moleculesC Jeffrey Calvitt, Daren S Levin, Benjamin T Shepperd, et al.
Advances in Therapy|July 11, 2015
Pharmacokinetics and Tolerability of Exenatide Delivered by 7-Day Continuous Subcutaneous Infusion in Healthy VolunteersGeorgios Vlasakakis, Susan L Johnson, Jiang Lin, et al.
Journal of Aerosol Medicine and Pulmonary Drug Delivery|April 8, 2025
Inhalable and Nasal Biologics: Analytical, Formulation, Development, and Regulatory ConsiderationsDavid Cipolla, Christopher J Gruenloh, Nani Kadrichu, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|April 26, 2011
Combining ion pairing agents for enhanced analysis of oligonucleotide therapeutics by reversed phase-ion pairing ultra performance liquid chromatography (UPLC)Daren S Levin, Benjamin T Shepperd, Christopher J Gruenloh
Oligonucleotides|October 28, 2010
Chemistry at the 2' position of constituent nucleotides controls degradation pathways of highly modified oligonucleotide moleculesC Jeffrey Calvitt, Daren S Levin, Benjamin T Shepperd, et al.
Advances in Therapy|July 11, 2015
Pharmacokinetics and Tolerability of Exenatide Delivered by 7-Day Continuous Subcutaneous Infusion in Healthy VolunteersGeorgios Vlasakakis, Susan L Johnson, Jiang Lin, et al.
Journal of Aerosol Medicine and Pulmonary Drug Delivery|April 8, 2025
Inhalable and Nasal Biologics: Analytical, Formulation, Development, and Regulatory ConsiderationsDavid Cipolla, Christopher J Gruenloh, Nani Kadrichu, et al.
Pageof 1